Literature DB >> 20974536

Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein.

Zvi Hayouka1, Mattan Hurevich, Aviad Levin, Hadar Benyamini, Anat Iosub, Michal Maes, Deborah E Shalev, Abraham Loyter, Chaim Gilon, Assaf Friedler.   

Abstract

Restricting linear peptides to their bioactive conformation is an attractive way of improving their stability and activity. We used a cyclic peptide library with conformational diversity for selecting an active and stable peptide that mimics the structure and activity of the HIV-1 integrase (IN) binding loop from its cellular cofactor LEDGF/p75 (residues 361-370). All peptides in the library had the same primary sequence, and differed only in their conformation. Library screening revealed that the ring size and linker structure had a huge effect on the conformation, binding and activity of the peptides. One of the cyclic peptides, c(MZ 4-1), was a potent and stable inhibitor of IN activity in vitro and in cells even after 8 days. The NMR structure of c(MZ 4-1) showed that it obtains a bioactive conformation that is similar to the parent site in LEDGF/p75.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20974536     DOI: 10.1016/j.bmc.2010.09.046

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  15 in total

Review 1.  Targeting protein-protein interfaces using macrocyclic peptides.

Authors:  Meng Gao; Kui Cheng; Hang Yin
Journal:  Biopolymers       Date:  2015-07       Impact factor: 2.505

2.  Potent Inhibition of Hepatitis E Virus Release by a Cyclic Peptide Inhibitor of the Interaction between Viral Open Reading Frame 3 Protein and Host Tumor Susceptibility Gene 101.

Authors:  Saumya Anang; Nidhi Kaushik; Smita Hingane; Anita Kumari; Jyoti Gupta; Shailendra Asthana; Baibaswata Nayak; C T Ranjith-Kumar; Milan Surjit
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

Review 3.  Peptides and peptidomimetics as immunomodulators.

Authors:  Ameya S Gokhale; Seetharama Satyanarayanajois
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

4.  In Silico Analysis of Peptide Macrocycle -Protein Interactions.

Authors:  Margaret M Hurley; Meagan C Small
Journal:  Methods Mol Biol       Date:  2022

5.  Design of cell-permeable stapled peptides as HIV-1 integrase inhibitors.

Authors:  Ya-Qiu Long; Shao-Xu Huang; Zahrah Zawahir; Zhong-Liang Xu; Huiyuan Li; Tino W Sanchez; Ying Zhi; Stephanie De Houwer; Frauke Christ; Zeger Debyser; Nouri Neamati
Journal:  J Med Chem       Date:  2013-06-24       Impact factor: 7.446

6.  A New Class of Allosteric HIV-1 Integrase Inhibitors Identified by Crystallographic Fragment Screening of the Catalytic Core Domain.

Authors:  Disha Patel; Janet Antwi; Pratibha C Koneru; Erik Serrao; Stefano Forli; Jacques J Kessl; Lei Feng; Nanjie Deng; Ronald M Levy; James R Fuchs; Arthur J Olson; Alan N Engelman; Joseph D Bauman; Mamuka Kvaratskhelia; Eddy Arnold
Journal:  J Biol Chem       Date:  2016-09-19       Impact factor: 5.157

7.  Specific recognition of p53 tetramers by peptides derived from p53 interacting proteins.

Authors:  Ronen Gabizon; Tobias Brandt; Shahar Sukenik; Noa Lahav; Mario Lebendiker; Deborah E Shalev; Dmitry Veprintsev; Assaf Friedler
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

Review 8.  Cyclic peptides as therapeutic agents and biochemical tools.

Authors:  Sang Hoon Joo
Journal:  Biomol Ther (Seoul)       Date:  2012-01       Impact factor: 4.634

9.  Inhibiting the HIV integration process: past, present, and the future.

Authors:  Roberto Di Santo
Journal:  J Med Chem       Date:  2013-09-25       Impact factor: 7.446

Review 10.  Allosteric modulation of protein oligomerization: an emerging approach to drug design.

Authors:  Ronen Gabizon; Assaf Friedler
Journal:  Front Chem       Date:  2014-03-24       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.